How many clinical trials are tracked for eating disorders?

27 trials are tracked, 1 with published results.

eating disorders Research

Eating disorders: what the trials found

Pharmacological interventions show varying results for specific conditions and symptoms. Fluoxetine was associated with a statistically significant reduction in psychological symptoms as measured by the Beck Anxiety Inventory (BAI) over treatment periods ². Olanzapine was evaluated in multiple trials, including one specifically focused on its administration ¹⁰, though specific outcome metrics for these studies were not detailed beyond the intervention itself.

In bone health research, Romosozumab demonstrated a significant increase in postero-anterior lumbar spine bone mineral density at 12 months compared to the control group ⁵. Denosumab also showed statistically significant results in postero-anterior lumbar spine bone mineral density measurements ⁶, although its specific percentage change from baseline did not reach statistical significance.

Neuroimaging studies using [11C]raclopride identified significant differences in Dopamine D2/D3 receptor binding after amphetamine administration ³. Additionally, a study on weight management showed that Olanzapine was associated with a change in weight at 12 weeks compared to the control group ⁴.

For the clinician treating this condition

Fluoxetine is associated with significant improvements in anxiety symptoms (BAI) in relevant patient populations ².
Romosozumab shows a statistically significant positive impact on lumbar spine bone mineral density at 12 months ⁵.
Cognitive restructuring and peer mentorship have shown statistically significant improvements in emotional regulation and eating disorder-specific symptoms, respectively [21, 22].

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.